Pembina Pipeline Corp. Stock Rises Tuesday, Outperforms Market
Dow Jones2026/10/06 20:34This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Pembina Pipeline Corp. PPL inched 0.84% higher to C$66.37 Tuesday, in what proved to be an all-around favorable trading session for the Canadian market, with the S&P/TSX Composite Index rising 0.37% to 35,649.51. Pembina Pipeline Corp. closed 8.7% below its 52-week high of C$72.72, which the company achieved on July 24th. Trading volume of 2.1 M shares remained below its 50-day average volume of 2.2 M. Data source: Dow Jones Market Data, FactSet. Data compiled October 6, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires October 06, 2026 16:34 ET (20:34 GMT)
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Pembina Pipeline Corp. PPL inched 0.84% higher to C$66.37 Tuesday, in what proved to be an all-around favorable trading session for the Canadian market, with the S&P/TSX Composite Index rising 0.37% to 35,649.51.
Pembina Pipeline Corp. closed 8.7% below its 52-week high of C$72.72, which the company achieved on July 24th.
Trading volume of 2.1 M shares remained below its 50-day average volume of 2.2 M.
Data source: Dow Jones Market Data, FactSet. Data compiled October 6, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
October 06, 2026 16:34 ET (20:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canadian Research Review - Aecon Group, Suncor Energy, Wellstar Technologies
FDA Accepts Aquestive’s Anaphylm Resubmission for Review
BUZZ - "Neutron" rocket launch delayed to 2027, Rocket Lab stock drops
